Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. announced that its lead drug, Rutherrin®, significantly enhanced the efficacy of the chemotherapy drug Cisplatin in treating chemotherapy-resistant Non-Small Cell Lung Cancer in a preclinical animal study. The combination treatment not only improved the drug’s effectiveness but also notably increased the survival rate of mice with aggressive lung tumors.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.